Caprelsa

• Caprelsa (vandetanib) is an oral kinase inhibitor primarily used to treat symptomatic or progressive medullary thyroid cancer.
• It works by targeting specific enzymes, such as the RET receptor tyrosine kinase, as well as VEGFR and EGFR, to inhibit cancer cell growth and blood vessel formation.
• Key Caprelsa drug information includes its oral administration and the need for careful monitoring due to potential side effects.
• Common Caprelsa uses and side effects involve gastrointestinal issues, skin reactions, and fatigue, with more serious risks like QT prolongation requiring close medical supervision.
• Patients undergoing treatment with Caprelsa require regular monitoring of cardiac function, electrolytes, and dermatological changes.

What is Caprelsa?

Caprelsa refers to vandetanib, an oral medication classified as a kinase inhibitor. It is a targeted therapy approved for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients who are ineligible for surgery or have advanced disease. As a Caprelsa medication, it works by interfering with the growth and spread of cancer cells by blocking the activity of specific enzymes, known as tyrosine kinases, that are crucial for cell proliferation and survival. Its primary role is in managing a rare form of thyroid cancer, offering a specialized treatment option for patients facing this challenging diagnosis.

Caprelsa: Mechanism of Action and Key Drug Information

Caprelsa functions by inhibiting multiple receptor tyrosine kinases that are involved in tumor growth, angiogenesis (the formation of new blood vessels that feed tumors), and tumor cell survival. Its primary mechanism of action involves targeting the rearranged during transfection (RET) proto-oncogene, which is often mutated or overexpressed in medullary thyroid cancer. Additionally, it inhibits vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) pathways. By blocking these pathways, Caprelsa helps to slow down tumor progression and reduce tumor size.

Regarding Caprelsa drug information, it is administered orally, typically once daily. The dosage and duration of treatment are determined by a healthcare professional based on the patient’s condition and response to therapy. Due to its mechanism of action, Caprelsa can have systemic effects, necessitating careful monitoring throughout treatment. This includes regular assessment of cardiac function, electrolyte levels, and thyroid-stimulating hormone (TSH) levels.

Caprelsa Uses and Potential Side Effects

The primary approved indication for Caprelsa uses and side effects is for the treatment of symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic. It is not intended for patients with asymptomatic or slowly progressing disease. The decision to initiate Caprelsa treatment is typically made after a thorough evaluation of the patient’s disease progression and overall health status.

Like all potent medications, Caprelsa carries a risk of potential side effects. Patients must be closely monitored for these adverse reactions. Common side effects often include:

• Diarrhea and nausea
• Skin rash and photosensitivity
• Fatigue and headache
• Hypertension (high blood pressure)
• Proteinuria (protein in the urine)

More serious side effects can occur, such as QT prolongation, a heart rhythm disorder that can be life-threatening. Due to this risk, electrocardiograms (ECGs) and electrolyte levels (potassium, magnesium, calcium) must be monitored before and during treatment. Other serious risks include interstitial lung disease and severe skin reactions. Patients should report any unusual symptoms to their healthcare provider immediately.